Australian Clinical Labs (ACL) H1 2026 earnings summary

Executive summary

• Revenue for the half-year was AUD 365.4 million, down 1% year-over-year, reflecting a focus on margin over volume in a subdued market.

• Underlying EBIT grew 2.4% to AUD 28 million, with margin expansion to 7.7%, driven by operational efficiency and productivity initiatives.

• Underlying NPAT increased 8.9% to AUD 13.2 million, and underlying EPS rose 12.8% to AUD 0.067, supported by share buybacks.

• Free cash flow before interest, tax, and financing was AUD 21 million, down year-over-year due to a one-off settlement and working capital movement.

• Capital returns to shareholders totaled AUD 27.8 million in H1, including dividends and buybacks, about 6% of market cap.

Financial highlights

• Revenue: AUD 365.4 million, down 1% year-over-year; underlying EBIT: AUD 28 million, up 2.4%, margin 7.7%.

• Underlying NPAT: AUD 13.2 million, up 8.9%; underlying EPS: AUD 0.067, up 12.8%.

• Statutory NPAT was AUD 5.7 million, down 51.7% year-over-year due to non-recurring items.

• Interim dividend declared: AUD 0.0375 per share, a 0.25 cent increase from prior period.

• Free cash flow before interest, tax, and financing was AUD 21 million, down 21.4% year-over-year.

Outlook and guidance

• FY26 revenue guidance updated to AUD 735–745 million, with underlying EBIT expected at AUD 66–69 million before gender undervaluation impacts.

• Gender undervaluation wage increases to impact FY26 EBIT by AUD 1.8 million; full-year margin expected at ~9% before this impact.

• H2 expected to be stronger than H1, with margin guidance of ~11% for 2H26.

• At least AUD 8 million of additional EBIT expected in FY27 from ongoing initiatives, including digitized billing and automation.

• Guidance excludes potential further costs from historical underpayments; any such costs will be taken below the line.